Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway

Nature Medicine

Volumn 11, Issue 1, 2005, Pages 71-76

  Insinga, Alessandra ^a   Monestiroli, Silvia ^a,b   Ronzoni, Simona ^a,b   Gelmetti, Vania ^c   Marchesi, Francesco ^a,b,d   Viale, Andrea ^a   Altucci, Lucia ^e   Nervi, Clara ^c   Minucci, Saverio ^a   Pelicci, Pier Giuseppe ^a,b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c S Raffaele Biomed Sci Pk of Rome   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; TRANSCRIPTION FACTOR RUNX1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VALPROIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MOUSE; MYELOID LEUKEMIA; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR SENSITIVITY; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HISTONE DEACETYLASES; LEUKEMIA, MYELOID; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 13444274622     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm1160     Document Type: Article

References (25)

1. Marks, P. et al. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer 1, 194-202 (2001).
2. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1, 287-299 (2002).
3. Johnstone, R.W. & Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4, 13-18 (2003).
4. Kelly, W.K., O'Connor, O.A. & Marks, P.A. Histone deacetylase inhibitors: from target to clinical trials. Expert Opin. Investig. Drugs 11, 1695-1713 (2002).
5. Marks, P.A., Richon, V.M. & Rifkind, R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J. Natl. Cancer Inst. 92, 1210-1216 (2000).
6. Grignani, F. et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391, 815-818 (1998).
7. Minucci, S. et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol. Cell 5, 811-820 (2000).
8. Lin, R.J. & Evans, R.M. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol. Cell 5, 821-830 (2000).
9. Minucci, S. et al. PML-RAR induces promyelocytic leukemias with high efficiency following retroviral gene transfer into purified murine hematopoietic progenitors. Blood 100, 2989-2995 (2002).
10. Melnick, A. & Licht, J.D. Deconstructing a disease: RARα, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93, 3167-3215 (1999).
11. Westervelt, P. & Ley, T.J. Seed versus soil: the importance of the target cell for transgenic models of human leukemias. Blood 93, 2143-2148 (1999).
12. Grignani, F. et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74, 423-431 (1993).
13. Ruthardt, M. et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RAR α) and PLZF-RAR α fusion proteins on retinoic acid signalling. Mol. Cell. Biol. 17, 4859-4869 (1997).
14. Casini, T. & Pelicci, P.G. A function of p21 during promyelocytic leukemia cell differentiation independent of COK inhibition and cell cycle arrest. Oncogene 18, 3235-3243 (1999).
15. Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079-1082 (2002).
16. Insinga, A. et al. Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J. 23, 1144-1154 (2004).
17. Walczak, H. & Krammer, P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256, 58-66 (2000).
18. Ashkenazi, A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2, 420-430 (2002).
19. LeBlanc, H.N. & Ashkenazi, A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10, 66-75 (2003).
20. Ferrara, F.F. et al. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res. 61, 2-7 (2001).
21. Johnstone, R.W., Ruefli, A.A. & Lowe, S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108, 153-164 (2002).
22. Westervelt, P. et al. High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARα expression. Blood 102, 1857-1865 (2003).
23. Yuan, Y. et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc. Nat.l Acad. Sci. USA 98, 10398-10403 (2001).
24. Higuchi, M. et al. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell 1, 63-74 (2002).
25. Song, E. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347-351 (2003).